Authors: Bergman, A Einbeigi, Z Olofsson, U Taib, Z Wallgren, A Karlsson, P Wahlstrom, J Martinsson, T Nordling, M

Citation: A. Bergman et al., The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation, EUR J HUM G, 9(10), 2001, pp. 787-793

Authors: Brezicka, T Einbeigi, Z

Citation: T. Brezicka et Z. Einbeigi, Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro, TUMOR BIOL, 22(2), 2001, pp. 97-103

Authors: Einbeigi, Z Bergman, A Kindblom, LG Martinsson, T Meis-Kindblom, JM Nordling, M Suurkula, M Wahlstrom, J Wallgren, A Karlsson, P

Citation: Z. Einbeigi et al., A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer, EUR J CANC, 37(15), 2001, pp. 1904-1909

Authors: Loman, N Johannsson, A Bendahl, PO Dahl, N Einbeigi, Z Gerdes, AM Borg, A Olsson, H

Citation: N. Loman et al., Prognosis and clinical presentation of BRCA2-associated breast cancer, EUR J CANC, 36(11), 2000, pp. 1365-1373

Authors: Brezicka, T Einbeigi, Z Bergman, B

Citation: T. Brezicka et al., Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells, CANCER IMMU, 49(4-5), 2000, pp. 235-242

Authors: Einbeigi, Z Kindblom, J Kindblom, LG Martinsson, T Suurkula, M Wahlstrom, J Wallgren, A Karlsson, P

Citation: Z. Einbeigi et al., A founder mutation of the BRCA1-gene in Western Sweden, DIS MARKER, 15(1-3), 1999, pp. 99-99